WO2010059140A1 - Topical cosmetic skin lightening compositions - Google Patents
Topical cosmetic skin lightening compositions Download PDFInfo
- Publication number
- WO2010059140A1 WO2010059140A1 PCT/US2008/012952 US2008012952W WO2010059140A1 WO 2010059140 A1 WO2010059140 A1 WO 2010059140A1 US 2008012952 W US2008012952 W US 2008012952W WO 2010059140 A1 WO2010059140 A1 WO 2010059140A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- extract
- topical cosmetic
- cosmetic composition
- skin
- sunscreen
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 222
- 239000002537 cosmetic Substances 0.000 title claims abstract description 141
- 230000000699 topical effect Effects 0.000 title claims abstract description 134
- 206010040829 Skin discolouration Diseases 0.000 title description 53
- 239000000284 extract Substances 0.000 claims abstract description 107
- 241001130943 Phyllanthus <Aves> Species 0.000 claims abstract description 67
- 229940069445 licorice extract Drugs 0.000 claims abstract description 35
- 238000000034 method Methods 0.000 claims abstract description 35
- 241000132028 Bellis Species 0.000 claims abstract description 30
- 239000000516 sunscreening agent Substances 0.000 claims description 42
- 230000000475 sunscreen effect Effects 0.000 claims description 40
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 31
- 208000012641 Pigmentation disease Diseases 0.000 claims description 28
- 239000003963 antioxidant agent Substances 0.000 claims description 25
- 230000003078 antioxidant effect Effects 0.000 claims description 24
- 229940065602 bellis perennis extract Drugs 0.000 claims description 19
- 239000003974 emollient agent Substances 0.000 claims description 15
- 239000002562 thickening agent Substances 0.000 claims description 14
- YBGZDTIWKVFICR-JLHYYAGUSA-N Octyl 4-methoxycinnamic acid Chemical compound CCCCC(CC)COC(=O)\C=C\C1=CC=C(OC)C=C1 YBGZDTIWKVFICR-JLHYYAGUSA-N 0.000 claims description 13
- 229960001679 octinoxate Drugs 0.000 claims description 13
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 13
- QVVCOCBZICLMCH-UHFFFAOYSA-N 4-[2-(2h-benzotriazol-4-yl)-6-ethenyl-3,4,5-trimethylphenoxy]-2h-benzotriazole Chemical compound CC=1C(C)=C(C)C(C=C)=C(OC=2C=3N=NNC=3C=CC=2)C=1C1=CC=CC2=C1N=NN2 QVVCOCBZICLMCH-UHFFFAOYSA-N 0.000 claims description 11
- 241000132023 Bellis perennis Species 0.000 claims description 11
- 235000013399 edible fruits Nutrition 0.000 claims description 9
- 239000002304 perfume Substances 0.000 claims description 9
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 claims description 8
- 239000003995 emulsifying agent Substances 0.000 claims description 8
- 239000003755 preservative agent Substances 0.000 claims description 8
- 230000002335 preservative effect Effects 0.000 claims description 8
- 239000002738 chelating agent Substances 0.000 claims description 7
- 239000003002 pH adjusting agent Substances 0.000 claims description 7
- 239000003086 colorant Substances 0.000 claims description 5
- TYYHDKOVFSVWON-UHFFFAOYSA-N 2-butyl-2-methoxy-1,3-diphenylpropane-1,3-dione Chemical compound C=1C=CC=CC=1C(=O)C(OC)(CCCC)C(=O)C1=CC=CC=C1 TYYHDKOVFSVWON-UHFFFAOYSA-N 0.000 claims description 4
- WYWZRNAHINYAEF-UHFFFAOYSA-N Padimate O Chemical compound CCCCC(CC)COC(=O)C1=CC=C(N(C)C)C=C1 WYWZRNAHINYAEF-UHFFFAOYSA-N 0.000 claims description 4
- 229960002709 amiloxate Drugs 0.000 claims description 4
- UBNYRXMKIIGMKK-RMKNXTFCSA-N amiloxate Chemical compound COC1=CC=C(\C=C\C(=O)OCCC(C)C)C=C1 UBNYRXMKIIGMKK-RMKNXTFCSA-N 0.000 claims description 4
- 229960005193 avobenzone Drugs 0.000 claims description 4
- FDATWRLUYRHCJE-UHFFFAOYSA-N diethylamino hydroxybenzoyl hexyl benzoate Chemical compound CCCCCCOC(=O)C1=CC=CC=C1C(=O)C1=CC=C(N(CC)CC)C=C1O FDATWRLUYRHCJE-UHFFFAOYSA-N 0.000 claims description 4
- 229960001630 diethylamino hydroxybenzoyl hexyl benzoate Drugs 0.000 claims description 4
- 229960004881 homosalate Drugs 0.000 claims description 4
- FMJSMJQBSVNSBF-UHFFFAOYSA-N octocrylene Chemical group C=1C=CC=CC=1C(=C(C#N)C(=O)OCC(CC)CCCC)C1=CC=CC=C1 FMJSMJQBSVNSBF-UHFFFAOYSA-N 0.000 claims description 4
- 229960000601 octocrylene Drugs 0.000 claims description 4
- 229940100498 polysilicone-15 Drugs 0.000 claims description 4
- 229920002282 polysilicones-15 Polymers 0.000 claims description 4
- 239000011787 zinc oxide Substances 0.000 claims description 4
- 239000004909 Moisturizer Substances 0.000 claims description 3
- 239000003906 humectant Substances 0.000 claims description 3
- SOXAGEOHPCXXIO-DVOMOZLQSA-N menthyl anthranilate Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@H]1OC(=O)C1=CC=CC=C1N SOXAGEOHPCXXIO-DVOMOZLQSA-N 0.000 claims description 3
- 229960002248 meradimate Drugs 0.000 claims description 3
- 230000001333 moisturizer Effects 0.000 claims description 3
- 230000003287 optical effect Effects 0.000 claims description 3
- 239000003961 penetration enhancing agent Substances 0.000 claims description 3
- 239000003381 stabilizer Substances 0.000 claims description 3
- 239000000375 suspending agent Substances 0.000 claims description 2
- 239000001649 glycyrrhiza glabra l. absolute Substances 0.000 claims 1
- 229940051810 licorice root extract Drugs 0.000 claims 1
- 235000020725 licorice root extract Nutrition 0.000 claims 1
- 241000202807 Glycyrrhiza Species 0.000 abstract description 18
- LTINPJMVDKPJJI-UHFFFAOYSA-N iodinated glycerol Chemical compound CC(I)C1OCC(CO)O1 LTINPJMVDKPJJI-UHFFFAOYSA-N 0.000 abstract description 17
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 abstract description 6
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 abstract description 5
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 abstract description 4
- 229940010454 licorice Drugs 0.000 abstract description 3
- 210000003491 skin Anatomy 0.000 description 49
- QIGBRXMKCJKVMJ-UHFFFAOYSA-N Hydroquinone Chemical compound OC1=CC=C(O)C=C1 QIGBRXMKCJKVMJ-UHFFFAOYSA-N 0.000 description 36
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 27
- 238000009472 formulation Methods 0.000 description 26
- 235000006708 antioxidants Nutrition 0.000 description 24
- 239000008213 purified water Substances 0.000 description 18
- 208000017520 skin disease Diseases 0.000 description 17
- 108010038807 Oligopeptides Proteins 0.000 description 16
- 102000015636 Oligopeptides Human genes 0.000 description 16
- 239000013543 active substance Substances 0.000 description 16
- 238000011282 treatment Methods 0.000 description 16
- 238000011156 evaluation Methods 0.000 description 15
- 230000002195 synergetic effect Effects 0.000 description 15
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 14
- 238000002156 mixing Methods 0.000 description 14
- 238000012360 testing method Methods 0.000 description 14
- 239000000839 emulsion Substances 0.000 description 13
- 230000019612 pigmentation Effects 0.000 description 13
- XMSXQFUHVRWGNA-UHFFFAOYSA-N Decamethylcyclopentasiloxane Chemical compound C[Si]1(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O1 XMSXQFUHVRWGNA-UHFFFAOYSA-N 0.000 description 12
- 239000003795 chemical substances by application Substances 0.000 description 12
- 239000006071 cream Substances 0.000 description 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 11
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 11
- 241000196324 Embryophyta Species 0.000 description 10
- 229940008099 dimethicone Drugs 0.000 description 10
- 239000004205 dimethyl polysiloxane Substances 0.000 description 10
- 235000013870 dimethyl polysiloxane Nutrition 0.000 description 10
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 10
- 230000000694 effects Effects 0.000 description 9
- 238000000265 homogenisation Methods 0.000 description 9
- BEGLCMHJXHIJLR-UHFFFAOYSA-N methylisothiazolinone Chemical compound CN1SC=CC1=O BEGLCMHJXHIJLR-UHFFFAOYSA-N 0.000 description 9
- 239000012071 phase Substances 0.000 description 9
- 229940100555 2-methyl-4-isothiazolin-3-one Drugs 0.000 description 7
- 244000303040 Glycyrrhiza glabra Species 0.000 description 7
- 229960000541 cetyl alcohol Drugs 0.000 description 7
- 150000001875 compounds Chemical class 0.000 description 7
- 208000035475 disorder Diseases 0.000 description 7
- -1 for example Substances 0.000 description 7
- 239000003205 fragrance Substances 0.000 description 7
- 238000004519 manufacturing process Methods 0.000 description 7
- 230000000750 progressive effect Effects 0.000 description 7
- 210000002966 serum Anatomy 0.000 description 7
- OMIGHNLMNHATMP-UHFFFAOYSA-N 2-hydroxyethyl prop-2-enoate Chemical compound OCCOC(=O)C=C OMIGHNLMNHATMP-UHFFFAOYSA-N 0.000 description 6
- QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 description 6
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 6
- 229920001214 Polysorbate 60 Polymers 0.000 description 6
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 6
- 239000004480 active ingredient Substances 0.000 description 6
- 238000013019 agitation Methods 0.000 description 6
- 239000008346 aqueous phase Substances 0.000 description 6
- 239000007854 depigmenting agent Substances 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 208000000069 hyperpigmentation Diseases 0.000 description 6
- 230000003810 hyperpigmentation Effects 0.000 description 6
- 239000003112 inhibitor Substances 0.000 description 6
- 239000003921 oil Substances 0.000 description 6
- 229960005323 phenoxyethanol Drugs 0.000 description 6
- 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 description 6
- 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 description 6
- 229940113124 polysorbate 60 Drugs 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 230000008569 process Effects 0.000 description 6
- 239000003981 vehicle Substances 0.000 description 6
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 5
- 208000003351 Melanosis Diseases 0.000 description 5
- 229920001577 copolymer Polymers 0.000 description 5
- 229920006037 cross link polymer Polymers 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 210000002752 melanocyte Anatomy 0.000 description 5
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 5
- 230000035935 pregnancy Effects 0.000 description 5
- 229910052708 sodium Inorganic materials 0.000 description 5
- 239000011734 sodium Substances 0.000 description 5
- 229940032094 squalane Drugs 0.000 description 5
- 238000003860 storage Methods 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- 239000004322 Butylated hydroxytoluene Substances 0.000 description 4
- 206010008570 Chloasma Diseases 0.000 description 4
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 4
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 4
- 239000003125 aqueous solvent Substances 0.000 description 4
- 235000010354 butylated hydroxytoluene Nutrition 0.000 description 4
- 229940095259 butylated hydroxytoluene Drugs 0.000 description 4
- 229940083913 c14-22 alcohols Drugs 0.000 description 4
- 239000000969 carrier Substances 0.000 description 4
- 229940086555 cyclomethicone Drugs 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 239000012530 fluid Substances 0.000 description 4
- 208000013403 hyperactivity Diseases 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 230000037311 normal skin Effects 0.000 description 4
- 230000005855 radiation Effects 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 150000003839 salts Chemical class 0.000 description 4
- 150000007949 saponins Chemical class 0.000 description 4
- 229920001285 xanthan gum Polymers 0.000 description 4
- 239000000230 xanthan gum Substances 0.000 description 4
- 229940082509 xanthan gum Drugs 0.000 description 4
- 235000010493 xanthan gum Nutrition 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 240000004670 Glycyrrhiza echinata Species 0.000 description 3
- 108010050808 Procollagen Proteins 0.000 description 3
- 206010047642 Vitiligo Diseases 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000004737 colorimetric analysis Methods 0.000 description 3
- 230000035614 depigmentation Effects 0.000 description 3
- 239000006185 dispersion Substances 0.000 description 3
- 150000002148 esters Chemical class 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 206010024217 lentigo Diseases 0.000 description 3
- 230000003061 melanogenesis Effects 0.000 description 3
- 229920001296 polysiloxane Polymers 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 108010005075 proelastin Proteins 0.000 description 3
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 3
- 229940001584 sodium metabisulfite Drugs 0.000 description 3
- 235000010262 sodium metabisulphite Nutrition 0.000 description 3
- 239000012453 solvate Substances 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 239000011782 vitamin Substances 0.000 description 3
- 229930003231 vitamin Natural products 0.000 description 3
- 235000013343 vitamin Nutrition 0.000 description 3
- 229940088594 vitamin Drugs 0.000 description 3
- 206010003694 Atrophy Diseases 0.000 description 2
- JDRSMPFHFNXQRB-CMTNHCDUSA-N Decyl beta-D-threo-hexopyranoside Chemical compound CCCCCCCCCCO[C@@H]1O[C@H](CO)C(O)[C@H](O)C1O JDRSMPFHFNXQRB-CMTNHCDUSA-N 0.000 description 2
- 239000003109 Disodium ethylene diamine tetraacetate Substances 0.000 description 2
- 206010015150 Erythema Diseases 0.000 description 2
- 229940123457 Free radical scavenger Drugs 0.000 description 2
- 229920001202 Inulin Polymers 0.000 description 2
- 206010024380 Leukoderma Diseases 0.000 description 2
- 244000119321 Phyllanthus reticulatus Species 0.000 description 2
- 244000038594 Phyllanthus urinaria Species 0.000 description 2
- 108010039918 Polylysine Proteins 0.000 description 2
- 206010070834 Sensitisation Diseases 0.000 description 2
- 206010064127 Solar lentigo Diseases 0.000 description 2
- 102000003425 Tyrosinase Human genes 0.000 description 2
- 108060008724 Tyrosinase Proteins 0.000 description 2
- 239000000443 aerosol Substances 0.000 description 2
- 239000000058 anti acne agent Substances 0.000 description 2
- 239000002260 anti-inflammatory agent Substances 0.000 description 2
- 229940121363 anti-inflammatory agent Drugs 0.000 description 2
- 230000001153 anti-wrinkle effect Effects 0.000 description 2
- 229940124340 antiacne agent Drugs 0.000 description 2
- 239000004599 antimicrobial Substances 0.000 description 2
- 239000013011 aqueous formulation Substances 0.000 description 2
- 230000000975 bioactive effect Effects 0.000 description 2
- FQUNFJULCYSSOP-UHFFFAOYSA-N bisoctrizole Chemical compound N1=C2C=CC=CC2=NN1C1=CC(C(C)(C)CC(C)(C)C)=CC(CC=2C(=C(C=C(C=2)C(C)(C)CC(C)(C)C)N2N=C3C=CC=CC3=N2)O)=C1O FQUNFJULCYSSOP-UHFFFAOYSA-N 0.000 description 2
- 238000005282 brightening Methods 0.000 description 2
- 239000012876 carrier material Substances 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 229940073499 decyl glucoside Drugs 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 235000019301 disodium ethylene diamine tetraacetate Nutrition 0.000 description 2
- NOPFSRXAKWQILS-UHFFFAOYSA-N docosan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCCCCCO NOPFSRXAKWQILS-UHFFFAOYSA-N 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 231100000321 erythema Toxicity 0.000 description 2
- QOLIPNRNLBQTAU-UHFFFAOYSA-N flavan Chemical compound C1CC2=CC=CC=C2OC1C1=CC=CC=C1 QOLIPNRNLBQTAU-UHFFFAOYSA-N 0.000 description 2
- 229930182486 flavonoid glycoside Natural products 0.000 description 2
- 150000007955 flavonoid glycosides Chemical class 0.000 description 2
- 239000003349 gelling agent Substances 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 description 2
- 229940029339 inulin Drugs 0.000 description 2
- 230000007794 irritation Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000006210 lotion Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 238000004806 packaging method and process Methods 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 150000007965 phenolic acids Chemical class 0.000 description 2
- 208000017983 photosensitivity disease Diseases 0.000 description 2
- 231100000434 photosensitization Toxicity 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- 150000008442 polyphenolic compounds Chemical class 0.000 description 2
- 235000013824 polyphenols Nutrition 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 230000008092 positive effect Effects 0.000 description 2
- 229960003387 progesterone Drugs 0.000 description 2
- 239000000186 progesterone Substances 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
- 239000002516 radical scavenger Substances 0.000 description 2
- 229930182490 saponin Natural products 0.000 description 2
- 235000017709 saponins Nutrition 0.000 description 2
- 230000037390 scarring Effects 0.000 description 2
- 230000008313 sensitization Effects 0.000 description 2
- 230000036555 skin type Effects 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- UEUXEKPTXMALOB-UHFFFAOYSA-J tetrasodium;2-[2-[bis(carboxylatomethyl)amino]ethyl-(carboxylatomethyl)amino]acetate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O UEUXEKPTXMALOB-UHFFFAOYSA-J 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000011200 topical administration Methods 0.000 description 2
- 150000003722 vitamin derivatives Chemical class 0.000 description 2
- 229910052724 xenon Inorganic materials 0.000 description 2
- FHNFHKCVQCLJFQ-UHFFFAOYSA-N xenon atom Chemical compound [Xe] FHNFHKCVQCLJFQ-UHFFFAOYSA-N 0.000 description 2
- YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 description 1
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 1
- NCIAZCLIFWUDPR-UHFFFAOYSA-N 2-butyl-3,4,5,6-tetramethylphenol Chemical compound CCCCC1=C(C)C(C)=C(C)C(C)=C1O NCIAZCLIFWUDPR-UHFFFAOYSA-N 0.000 description 1
- 244000058084 Aegle marmelos Species 0.000 description 1
- 235000003930 Aegle marmelos Nutrition 0.000 description 1
- 102100022712 Alpha-1-antitrypsin Human genes 0.000 description 1
- 241001251706 Astranthium integrifolium Species 0.000 description 1
- 206010003645 Atopy Diseases 0.000 description 1
- 241001425056 Bellis rotundifolia Species 0.000 description 1
- JMGZEFIQIZZSBH-UHFFFAOYSA-N Bioquercetin Natural products CC1OC(OCC(O)C2OC(OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5)C(O)C2O)C(O)C(O)C1O JMGZEFIQIZZSBH-UHFFFAOYSA-N 0.000 description 1
- 241000195493 Cryptophyta Species 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 235000015489 Emblica officinalis Nutrition 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 206010014970 Ephelides Diseases 0.000 description 1
- 241000221017 Euphorbiaceae Species 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 241000220485 Fabaceae Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 235000005883 Glycyrrhiza glabra var glandulifera Nutrition 0.000 description 1
- 240000008693 Glycyrrhiza lepidota Species 0.000 description 1
- 235000000554 Glycyrrhiza uralensis Nutrition 0.000 description 1
- 239000012981 Hank's balanced salt solution Substances 0.000 description 1
- 208000009889 Herpes Simplex Diseases 0.000 description 1
- 101000823116 Homo sapiens Alpha-1-antitrypsin Proteins 0.000 description 1
- 101001010513 Homo sapiens Leukocyte elastase inhibitor Proteins 0.000 description 1
- 206010027145 Melanocytic naevus Diseases 0.000 description 1
- 208000007256 Nevus Diseases 0.000 description 1
- 230000010718 Oxidation Activity Effects 0.000 description 1
- 241001579678 Panthea coenobita Species 0.000 description 1
- IYMHVUYNBVWXKH-ZITZVVOASA-N Pedunculagin Chemical compound C([C@H]1OC2O)OC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)O[C@H]1[C@H]1[C@H]2OC(=O)C2=CC(O)=C(O)C(O)=C2C2=C(O)C(O)=C(O)C=C2C(=O)O1 IYMHVUYNBVWXKH-ZITZVVOASA-N 0.000 description 1
- 229920000158 Pedunculagin Polymers 0.000 description 1
- HVXQPVRDPFKKHP-UHFFFAOYSA-N Pedunculagin Natural products OC1C2COC(=O)c3cc(O)c(O)c(O)c3c4c(O)c(O)c(O)cc4C(=O)OC(O2)C5OC(=O)c6cc(O)c(O)c(O)c6c7c(O)c(O)c(O)cc7C(=O)OC15 HVXQPVRDPFKKHP-UHFFFAOYSA-N 0.000 description 1
- 241001331502 Phyllanthus casticum Species 0.000 description 1
- 240000009120 Phyllanthus emblica Species 0.000 description 1
- 241001331944 Phyllanthus madagascariensis Species 0.000 description 1
- 241001517997 Polypodium glycyrrhiza Species 0.000 description 1
- 229920000319 Punigluconin Polymers 0.000 description 1
- MTFGSHWJTZMFBZ-UHFFFAOYSA-N Punigluconin Natural products OC(C(OC(=O)c1cc(O)c(O)c(O)c1)C(=O)O)C2OC(=O)c3cc(O)c(O)c(O)c3c4c(O)c(O)c(O)cc4C(=O)OCC2O MTFGSHWJTZMFBZ-UHFFFAOYSA-N 0.000 description 1
- 229910000831 Steel Inorganic materials 0.000 description 1
- 239000004809 Teflon Substances 0.000 description 1
- 229920006362 Teflon® Polymers 0.000 description 1
- BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 description 1
- 208000024780 Urticaria Diseases 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- UEHSSTYZXFBDNL-DNOBIOAJSA-N [(10R,15R)-3,4,5,21,22,23-hexahydroxy-8,13,18-trioxo-12-(3,4,5-trihydroxybenzoyl)oxy-9,14,17-trioxatetracyclo[17.4.0.02,7.010,15]tricosa-1(23),2,4,6,11,19,21-heptaen-11-yl] 3,4,5-trihydroxybenzoate Chemical compound Oc1cc(cc(O)c1O)C(=O)OC1=C(OC(=O)c2cc(O)c(O)c(O)c2)C(=O)O[C@@H]2COC(=O)c3cc(O)c(O)c(O)c3-c3c(O)c(O)c(O)cc3C(=O)O[C@@H]12 UEHSSTYZXFBDNL-DNOBIOAJSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000002390 adhesive tape Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 125000005233 alkylalcohol group Chemical group 0.000 description 1
- 239000000956 alloy Substances 0.000 description 1
- 229910045601 alloy Inorganic materials 0.000 description 1
- 229940061720 alpha hydroxy acid Drugs 0.000 description 1
- 150000001280 alpha hydroxy acids Chemical class 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- RWZYAGGXGHYGMB-UHFFFAOYSA-N anthranilic acid Chemical compound NC1=CC=CC=C1C(O)=O RWZYAGGXGHYGMB-UHFFFAOYSA-N 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 229940053200 antiepileptics fatty acid derivative Drugs 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- GDVRUDXLQBVIKP-UHFFFAOYSA-N beta-D-glucogallin Natural products OC1C(O)C(O)C(CO)OC1OC(=O)C1=CC(O)=C(O)C(O)=C1 GDVRUDXLQBVIKP-UHFFFAOYSA-N 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 239000000919 ceramic Substances 0.000 description 1
- 229940106189 ceramide Drugs 0.000 description 1
- 150000001783 ceramides Chemical class 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000009920 chelation Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000005515 coenzyme Substances 0.000 description 1
- 229960002424 collagenase Drugs 0.000 description 1
- 238000010835 comparative analysis Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 239000008406 cosmetic ingredient Substances 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- SVYWZVZMBHFNGC-UHFFFAOYSA-N emblicanin-B Natural products OC1C(O)C(=O)OC1C(C(O)=O)OC(=O)C1=CC(O)=C(O)C(O)=C1 SVYWZVZMBHFNGC-UHFFFAOYSA-N 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- IVTMALDHFAHOGL-UHFFFAOYSA-N eriodictyol 7-O-rutinoside Natural products OC1C(O)C(O)C(C)OC1OCC1C(O)C(O)C(O)C(OC=2C=C3C(C(C(O)=C(O3)C=3C=C(O)C(O)=CC=3)=O)=C(O)C=2)O1 IVTMALDHFAHOGL-UHFFFAOYSA-N 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 238000010579 first pass effect Methods 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 238000005187 foaming Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 229930182478 glucoside Natural products 0.000 description 1
- 229940075529 glyceryl stearate Drugs 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- JEGUKCSWCFPDGT-UHFFFAOYSA-N h2o hydrate Chemical compound O.O JEGUKCSWCFPDGT-UHFFFAOYSA-N 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 230000001861 immunosuppressant effect Effects 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 239000005414 inactive ingredient Substances 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 229940042040 innovative drug Drugs 0.000 description 1
- XUGNVMKQXJXZCD-UHFFFAOYSA-N isopropyl palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC(C)C XUGNVMKQXJXZCD-UHFFFAOYSA-N 0.000 description 1
- 239000003410 keratolytic agent Substances 0.000 description 1
- 235000021374 legumes Nutrition 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 206010025135 lupus erythematosus Diseases 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 239000002077 nanosphere Substances 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- DXGLGDHPHMLXJC-UHFFFAOYSA-N oxybenzone Chemical compound OC1=CC(OC)=CC=C1C(=O)C1=CC=CC=C1 DXGLGDHPHMLXJC-UHFFFAOYSA-N 0.000 description 1
- 229960001173 oxybenzone Drugs 0.000 description 1
- IYMHVUYNBVWXKH-UHFFFAOYSA-N pedunculagin I isomer Natural products OC1OC2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C2C1OC(=O)C1=CC(O)=C(O)C(O)=C1C1=C(O)C(O)=C(O)C=C1C(=O)O2 IYMHVUYNBVWXKH-UHFFFAOYSA-N 0.000 description 1
- 229940100460 peg-100 stearate Drugs 0.000 description 1
- 230000002165 photosensitisation Effects 0.000 description 1
- 239000003504 photosensitizing agent Substances 0.000 description 1
- 231100000760 phototoxic Toxicity 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- RMGVATURDVPNOZ-UHFFFAOYSA-M potassium;hexadecyl hydrogen phosphate Chemical compound [K+].CCCCCCCCCCCCCCCCOP(O)([O-])=O RMGVATURDVPNOZ-UHFFFAOYSA-M 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000002250 progressing effect Effects 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- KZEYIYXACMUTRM-WIMKJKQSSA-N punigluconin Chemical compound O([C@@H]([C@@H]1OC(=O)C2=CC(O)=C(O)C(O)=C2C2=C(O)C(O)=C(O)C=C2C(=O)OC[C@H]1O)[C@@H](OC(=O)C=1C=C(O)C(O)=C(O)C=1)C(O)=O)C(=O)C1=CC(O)=C(O)C(O)=C1 KZEYIYXACMUTRM-WIMKJKQSSA-N 0.000 description 1
- FDRQPMVGJOQVTL-UHFFFAOYSA-N quercetin rutinoside Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 FDRQPMVGJOQVTL-UHFFFAOYSA-N 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 230000029219 regulation of pH Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- IKGXIBQEEMLURG-BKUODXTLSA-N rutin Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@@H]1OC[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-BKUODXTLSA-N 0.000 description 1
- ALABRVAAKCSLSC-UHFFFAOYSA-N rutin Natural products CC1OC(OCC2OC(O)C(O)C(O)C2O)C(O)C(O)C1OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5 ALABRVAAKCSLSC-UHFFFAOYSA-N 0.000 description 1
- 235000005493 rutin Nutrition 0.000 description 1
- 229960004555 rutoside Drugs 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000010008 shearing Methods 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- 229940104256 sodium taurate Drugs 0.000 description 1
- GWLWWNLFFNJPDP-UHFFFAOYSA-M sodium;2-aminoethanesulfonate Chemical compound [Na+].NCCS([O-])(=O)=O GWLWWNLFFNJPDP-UHFFFAOYSA-M 0.000 description 1
- FWFUWXVFYKCSQA-UHFFFAOYSA-M sodium;2-methyl-2-(prop-2-enoylamino)propane-1-sulfonate Chemical compound [Na+].[O-]S(=O)(=O)CC(C)(C)NC(=O)C=C FWFUWXVFYKCSQA-UHFFFAOYSA-M 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 229940031439 squalene Drugs 0.000 description 1
- TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010959 steel Substances 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 229920001864 tannin Polymers 0.000 description 1
- 235000018553 tannin Nutrition 0.000 description 1
- 239000001648 tannin Substances 0.000 description 1
- HLZKNKRTKFSKGZ-UHFFFAOYSA-N tetradecan-1-ol Chemical compound CCCCCCCCCCCCCCO HLZKNKRTKFSKGZ-UHFFFAOYSA-N 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 239000006208 topical dosage form Substances 0.000 description 1
- 239000012049 topical pharmaceutical composition Substances 0.000 description 1
- 230000002110 toxicologic effect Effects 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- 230000037303 wrinkles Effects 0.000 description 1
- 229960001296 zinc oxide Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9706—Algae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
Definitions
- compositions comprising plant extracts. These compositions are used for topical cosmetic applications, particularly to treat undesired skin pigmentation.
- Topical cosmetic skin lightening compositions that are safe and effective are particularly desirable for treating undesirable skin pigmentation, including for example, regional hyperpigmentation caused by melanocyte hyperactivity such as idiopathic melasma occurring during pregnancy (mask of pregnancy or chloasma) or secondary to estrogen-progesterone contraception; local hyperpigmentation caused by benign melanocyte hyperactivity and proliferation such as lentigo senilis, known as liver spots; accidental hyperpigmentation such as post-lesional photosensitization and scarring; skin ageing (for example lentigines seniles); and certain forms of leukoderma such as vitiligo where, if the injured skin cannot be repigmented, the residual zones of normal skin are lightened or depigmented to impart a homogeneous color to the entire skin.
- melanocyte hyperactivity such as idiopathic melasma occurring during pregnancy (mask of pregnancy or chloasma) or secondary to estrogen-progesterone
- U.S. Published Patent Application No. 2008/0050459 describes a cosmetic composition comprising an extract of Phyllanthus Embilica, an extract of Bellis Perrenis, an extract of Glycyrrhiza Glabra, and requiring at least one oligopeptide to achieve its cosmetic effect for the combined cosmetic treatment of fine lines and wrinkles, and/or skin brightening.
- Suitable oligopeptides are described as those having a suitable molecular weight so that they are able to act as carriers of Phyllanthus Embilica extract and penetrate skin to maximize the efficacy.
- the only oligopeptides described in the publication for achieving the cosmetic composition are oligopeptide-4 (pro-collagen oligopeptide) and oligopeptide-5 (pro-elastin oligopeptide).
- the present subject matter relates generally to topical cosmetic compositions useful for treating various skin disorders or conditions associated with undesired skin pigmentation. Further, the present subject matter relates to topical cosmetic compositions useful for cosmetic lightening of skin areas whose pigmentation is adequate for the individual skin type.
- the present subject matter relates to a topical cosmetic composition, comprising, consisting essentially of, or consisting of a Phyllanthus extract; a Bellis extract; and a licorice extract.
- the cosmetic composition does not comprise at least one oligopeptide.
- the cosmetic composition does not comprise at least one oligopeptide that is not normally present in Phyllanthus extract, Bellis extract, or licorice extract.
- the cosmetic composition does not comprise oligopeptide-4 (pro-collagen oligopeptide) or oligopeptide-5 (pro-elastin oligopeptide).
- the cosmetic composition does not comprise at least one oligopeptide having a suitable molecular weight so that it is able to act as carrier of Phyllanthus Embilica extract and penetrate skin to maximize the efficacy.
- the present subject matter relates to a topical cosmetic composition, comprising, consisting essentially of, or consisting of a Phyllanthus embilica extract; a Bellis perennis extract; and a licorice extract.
- the present subject matter relates to a topical cosmetic composition, comprising, consisting essentially of, or consisting of a skin-lightening active component comprising, consisting essentially of, or consisting of a Phyllanthus extract, a Bellis extract, and a licorice extract; at least one sunscreen; and a cosmetically acceptable carrier.
- the present subject matter relates to a topical cosmetic composition, comprising, consisting essentially of, or consisting of a skin-lightening active component comprising, consisting essentially of, or consisting of a Phyllanthus embilica extract, a Bellis perennis extract, and a licorice extract; at least one sunscreen; and a cosmetically acceptable carrier.
- the present subject matter relates to a topical cosmetic composition, comprising, consisting essentially of, or consisting of a skin-lightening active component comprising, consisting essentially of, or consisting of a Phyllanthus extract, a Bellis extract, and a licorice extract; and a non-skin lightening component comprising at least one sunscreen.
- the present subject matter relates to a topical cosmetic composition, comprising, consisting essentially of, or consisting of a skin-lightening active component comprising, consisting essentially of, or consisting of a Phyllanthus embilica extract, a Bellis perennis extract, and a licorice extract; and a non-skin lightening component comprising at least one sunscreen.
- the present subject matter relates to a method of lightening skin pigmentation in a subject, comprising topically administering to skin of a subject in need thereof, a therapeutically effective amount of a topical cosmetic composition in accordance with the presently described subject matter.
- the present subject matter relates to a method of treating a skin disorder or condition in a subject, comprising topically administering to skin of a subject in need thereof a therapeutically effective amount of a topical cosmetic composition in accordance with the presently described subject matter.
- Figure 1 illustrates progressive lightening over time that becomes statistically significant after 21 days for Site B treated with 2 % hydroquinone.
- Figure 2 illustrates progressive lightening over time that becomes statistically significant after 14 days for Site E treated with the present topical cosmetic composition.
- Figure 3 illustrates progressive lightening (natural degradation of the synthesized melanin), without any significance over the experimental times for the control location (Site F) which was not treated.
- Figure 4 illustrates the comparison between the averages of the colorimetric values in treatments 1 (Site B) and 2 (Site E) and the control (Site F) over the evaluation times.
- Figure 5 illustrates photographs of clinical data supporting the colorimetric results in treatments 1 (Site B) and 2 (Site E) and the control (Site F) comparing evaluation times TO and T21.
- administering refers to any method which, in sound medical or cosmetic practice, delivers the composition to a subject in such a manner as to provide a positive effect on a dermatological disorder, condition, or appearance.
- the compositions can be administered such that they cover the entire area to be treated.
- aqueous solvent refers to a solvent such as water or containing water.
- Other dissolved components may be present in small amounts, such as, for example, salts, buffers, and other components understood by one of ordinary skill in the art to be optionally present in an aqueous solution.
- Anhydrous formulation refers to any formulation of the present topical cosmetic composition that does not contain water.
- Cosmetically acceptable refers to a non-toxic, inert, and/or physiologically compatible composition.
- an "effective amount” or a “therapeutically effective amount” of an active agent or ingredient refer to an amount of the active agent sufficient enough to have a positive effect on the area of application. Accordingly, these amounts are sufficient to modify the skin disorder, condition, or appearance to be treated but low enough to avoid serious side effects, within the scope of sound medical or dermatological advice.
- extract refers to one or more components isolated from a plant source in a fluid or powder form.
- the plant source can comprise or consist of the entire plant or one or more parts of the plant, for example, the plant fruit, flower, root, leaves, stems, and/or bark.
- a fluid or liquid extract can be dried, for example, spray dried or desiccated, to form a powder.
- the extract can be a mixture of one or more components from a plant in a fluid and/or powder form.
- non-skin lightening any compound, substance or composition; or agent; or component comprising, consisting essentially of, or consisting of one or more agents, substances, compounds and compositions, which upon topical application to skin does not depigment or lighten the skin.
- Such agents can include, for example, one or more active agents, for example, a sunscreen, an anti-acne agent, an anti-microbial agent, an anti-wrinkle agent, an anti-atrophy agent, an anti-inflammatory agent, and an optical brightener; and/or one or more cosmetically acceptable excipients, for example, a thickener, a chelating agent, a moisturizer, an emollient, a humectant, a gelling agent, a pH adjuster, a surfactant, a stabilizer, a vitamin, a penetration enhancer, a perfume, a coloring agent, and a solvent; and/or combinations thereof; as described herein.
- active agents for example, a sunscreen, an anti-acne agent, an anti-microbial agent, an anti-wrinkle agent, an anti-atrophy agent, an anti-inflammatory agent, and an optical brightener
- cosmetically acceptable excipients for example, a thickener, a chelating agent, a
- salts, esters, or solvates refers to free bases, salts, esters, or solvates of subject compound(s) which possesses the same pharmacological activity as the subject compound(s) and which are neither biologically nor otherwise undesirable.
- a salt, ester, or solvate can be formed with, for example, organic or inorganic acids. Water or oil-soluble or dispersible products are thereby obtained.
- oligopeptide refers to a peptide having a suitable molecular weight so that it is able to act as a carrier of Phyllanthus Embilica extract and penetrate skin. Oligopeptides that might act as carriers of Phyllanthus Embilica extract and penetrate skin include oligopeptide-4 (pro-collagen oligopeptide) and oligopeptide-5 (pro-elastin oligopeptide). As used herein, "oligopeptide” does not refer to any peptide that is normally present in Phyllanthus extract, Bellis extract, or licorice extract. It is noted that in an embodiment of the present subject matter, the cosmetic composition does not comprise at least one oligopeptide that is not normally present in Phyllanthus extract, Bellis extract, or licorice extract.
- serum refers to a hydrophilic liquid formulation.
- a serum may optionally be free from one or more of an emollient, a wax and a silicone.
- skin lightening agent refers to any compound, substance, or composition which upon topical application to skin lightens or depigments the skin.
- skin lightening agents can include, but are not limited to, pigmentation inhibitors, tyrosinase inhibitors, and melanocyte melanogenesis inhibitors.
- “synergistic skin lightening system” or “synergistic skin lightening component” refers to a skin lightening active component comprising, consisting essentially of, or consisting of a Phyllanthus embilica extract, a Bellis perennis extract, and a licorice extract, that exhibits synergistic skin lightening efficacy as compared to the skin lightening efficacy of each individual skin lightening active agent.
- the combination of these ingredients provides a greater than additive skin lightening effect.
- a “treatment” or “treating” of a skin disease, disorder, or condition encompasses alleviation of at least one symptom thereof, a reduction in the severity thereof, or the delay, prevention, or inhibition of the progression thereof. Treatment need not mean that the disease, disorder, or condition is totally cured.
- a useful composition herein needs only to reduce the severity of a skin disease, disorder, or condition, reduce the severity of symptoms associated therewith, provide improvement to a patient's quality of life, or delay, prevent, or inhibit the onset of a skin disease, disorder, or condition.
- the present subject matter relates to a topical cosmetic composition, comprising, consisting essentially of, or consisting of a Phyllanthus extract; a Bellis extract; and a licorice extract.
- the present topical cosmetic compositions can comprise or consist of a Phyllanthus extract, i.e., Phyllanthus embilica extract; a Bellis extract, i.e., a Bellis per ennis extract; and a licorice extract.
- Phyllanthus extract means an extract obtained from the fruit of a member of the
- Phyllanthus genus including for example, of Phyllanthus embilica, Phyllanthus niruri L, Phyllanthus elegans Wall, Phyllanthus iniruri, Phyllanthus reticulatus, Phyllanthus urinaria L., Phyllanthus reticulatus Poir, Phyllanthus conami Sw, Phyllanthus lathyroides H. B. K., Phyllanthus casticum Soy- Will, and Phyllanthus madagascariensis.
- Phyllanthus extract is a safe and effective natural antioxidant.
- “Phyllanthus embilica extract” means a standardized extract of Phyllanthus embilica, including for example, EMBLICA® (Merck KGaA, Darmstadt, Germany and EM industries, Inc., USA, an affiliate of Merck KGaA). Phyllanthus embilica is also commonly known as “Emblica officinalis Gaertn” and is a member of the family “Euphorbiaceae.” Phyllanthus embilica is a very rich source of vitamin C, having an ascorbic acid content in the range from 1000 to 1800 mg per 100 grams of fruit.
- Phyllanthus embilica extract is a safe and effective natural antioxidant that has no pro-oxidation activity and can exhibit dual functionality, i.e., chelation and antioxidant. Unlike most antioxidants that go from an active to an inactive form, Phyllanthus embilica extract can exhibit a cascading effect that provides long-lasting and stable antioxidant activity. Phyllanthus embilica extract can be produced by extracting premium quality fruits using a water-based process as described in U.S. Patent No. 6,124,268, incorporated herein by reference in its entirety. Phyllanthus embilica extract typically contains low-molecular weight tannins, namely Emblicanin A and Emblicanin B, along with Pedunculagin and Punigluconin, Rutin and Gallo-ellagitannoids.
- Bos extract means an extract obtained from a member of the Bellis genus, including for example, the extract obtained from the flowers of a member of the Bellis genus, for example, from Bellis perennis flowers and/or from Bellis rotundifolia L. flowers.
- the Bellis extract can comprise or consist of one or more bioactive molecules including saponins (triterpene glycosides), polyphenols (phenolic acid), flavonoid glycosides, polysaccharides and inulin.
- Bellis perennis extract means the extract obtained from Bellis perennis flowers that can comprise or consist of one or more bioactive molecules including saponins (triterpene glycosides), polyphenols (phenolic acid), flavonoid glycosides, polysaccharides and inulin.
- Suitable Bellis perennis extracts can include BELIDES® available from CLR Chemisches Laboratorium, Berlin, Germany. Bellis perennis is also commonly known as Bellis alpina Hegetschw., Bellis hortensis Mill., Bellis hybrida Ten., Bellis integrifolia DC, and Bellis scaposa Gilib.
- “Licorice extract” means an extract obtained from a member of the Glycyrrhiza genus, for example obtained from the root of a member of the Glycyrrhiza genus.
- the genus “Glycyrrhiza” is a member of the family "Fabaceae.
- Suitable Glycyrrhiza extracts can include the oil soluble licorice extract available from Bioland, Korea.
- Other suitable Glycyrrhiza extracts can be obtained from one or more of the following members of the Glycyrrhiza genus including Glycyrrhiza echinata L. (Chinese licorice), Glycyrrhiza glabra L.
- the present topical cosmetic composition can comprise or consist of a skin lightening active component that can comprise or consist of a Phyllanthus extract, a Bellis extract, and a licorice extract.
- the present topical cosmetic composition can comprise or consist of a skin lightening active component that can comprise or consist of a Phyllanthus embilica extract, a Bellis perennis extract, and a licorice extract.
- the present subject matter relates to a topical cosmetic composition wherein the total skin lightening active component is present in the topical cosmetic composition in an amount of from about 0.5% to about 43% by weight, from about 1% to about 30% by weight, from about 1.5% to about 23% by weight, from about 1.5% to about 15% by weight, from about 3% to about 10% by weight, from about 6% to about 8% by weight, or about 7.05% by weight, based on the total weight of the composition.
- the present subject matter relates to a topical cosmetic composition wherein the Phyllanthus extract, for example, the Phyllanthus embilica extract, is present in the topical cosmetic composition in an amount of from about 0.1% to about 8% by weight, from about 0.25% to about 4% by weight, from about 0.5% to about 3% by weight, from about 0.5% to about 2% by weight, from about 1% to about 2% by weight, or about 2% by weight, based on the total weight of the composition.
- the Phyllanthus extract for example, the Phyllanthus embilica extract
- the present subject matter relates to a topical cosmetic composition wherein the Bellis extract, for example, the Bellis perennis extract, is present in the topical cosmetic composition in an amount of from about 0.5% to about 30% by weight, from about 1% to about 20% by weight, from about 2% to about 10% by weight, from about 3% to about 7% by weight, from about 4% to about 6% by weight, or about 5.0% by weight, based on the total weight of the composition.
- the Bellis extract for example, the Bellis perennis extract
- the topical cosmetic composition in an amount of from about 0.5% to about 30% by weight, from about 1% to about 20% by weight, from about 2% to about 10% by weight, from about 3% to about 7% by weight, from about 4% to about 6% by weight, or about 5.0% by weight, based on the total weight of the composition.
- the present subject matter relates to a topical cosmetic composition wherein the licorice extract is present in the topical cosmetic composition in an amount of from about 0.005% to about 5% by weight, from about 0.01% to about 2% by weight, from about 0.01% to about 1% by weight, from about 0.02% to about 0.08% by weight, from about 0.03% to about 0.07% by weight, or about 0.05% by weight, based on the total weight of the composition.
- the present subject matter relates to a topical cosmetic composition
- the Phyllanthus extract for example, the Phyllanthus embilica extract
- the Bellis extract for example, the Bellis perennis extract
- the licorice extract is present in the topical cosmetic composition in an amount of from about 0.01 wt% to about 1 wt%.
- the present subject matter relates to a topical cosmetic composition, wherein the Phyllanthus embilica extract is present in the topical cosmetic composition in an amount of about 2 wt%; the Bellis perennis extract is present in an amount of about 5 wt%; and the licorice extract is present in the topical cosmetic composition in an amount of about 0.05 wt%.
- the present subject matter relates to a topical cosmetic composition, comprising, consisting essentially of, or consisting of a skin-lightening active component comprising, consisting essentially of, or consisting of a Phyllanthus extract, for example, a Phyllanthus embilica extract; a Bellis extract, for example, a Bellis perennis extract; and a licorice extract; at least one sunscreen; and a cosmetically acceptable carrier.
- the cosmetically acceptable carrier can comprise or consist of one or more cosmetically acceptable excipients.
- the present subject matter relates to a topical cosmetic composition, comprising, consisting essentially of, or consisting of a skin-lightening active component comprising, consisting essentially of, or consisting of a Phyllanthus extract, for example, a Phyllanthus embilica extract; a Bellis extract, for example, a Bellis perennis extract; and a licorice extract; and a non-skin lightening component.
- the non-skin lightening component can comprise or consist of one or more of an active agent, for example, a sunscreen; a cosmetically acceptable carrier; and/or a cosmetically acceptable excipient, as described herein.
- the present subject matter relates to a topical cosmetic composition in accordance with the subject matter described herein that can comprise one or more non-skin lightening active agents.
- the topical cosmetic composition and/or the cosmetically acceptable carrier and/or one or more cosmetically acceptable excipients can be free from any skin lightening agents other than a Phyllanthus extract, for example a Phyllanthus embilica extract; a Bellis extract, for example, a Bellis perennis extract; and licorice extract.
- the topical cosmetic composition and/or the cosmetically acceptable carrier and/or one or more cosmetically acceptable excipients can be free from any plant derived skin lightening agents other than a Phyllanthus extract, for example a Phyllanthus embilica extract; a Bellis extract, for example, a Bellis perennis extract; and licorice extract.
- the topical cosmetic composition and/or the cosmetically acceptable carrier and/or one or more cosmetically acceptable excipients can be free from any non-plant derived skin lightening agents.
- the present subject matter relates to a topical cosmetic composition, wherein the composition and/or a skin lightening active component and/or a non- skin lightening component, does not comprise hydroquinone or a derivative thereof, and/or does not comprise a polyorganosiloxane-containing epsilon-polylysine compound, and/or does not comprise a flavan.
- the present subject matter relates to a topical cosmetic composition that can comprise or consist of a synergistic skin lightening active component comprising, consisting essentially of, or consisting of a Phyllanthus extract, for example a Phyllanthus embilica extract; a Bellis extract, for example, a Bellis perennis extract; and licorice extract, wherein the synergistic skin lightening active component exhibits synergistic skin lightening efficacy as compared to the skin lightening efficacy of each individual skin lightening active agent.
- a synergistic skin lightening active component comprising, consisting essentially of, or consisting of a Phyllanthus extract, for example a Phyllanthus embilica extract; a Bellis extract, for example, a Bellis perennis extract; and licorice extract, wherein the synergistic skin lightening active component exhibits synergistic skin lightening efficacy as compared to the skin lightening effic
- the present subject matter relates to a synergistic skin lightening component for use in a topical cosmetic composition
- a synergistic skin lightening component for use in a topical cosmetic composition
- a topical cosmetic composition comprising, consisting essentially of, or consisting of a Phyllanthus extract, for example a Phyllanthus embilica extract; a Bellis extract, for example, a Bellis perennis extract; and licorice extract.
- the present subject matter relates to a synergistic skin lightening component for use in a topical cosmetic composition
- a synergistic skin lightening component for use in a topical cosmetic composition
- a Phyllanthus extract for example a Phyllanthus embilica extract
- a Bellis extract for example, a Bellis perennis extract
- licorice extract wherein the synergistic skin lightening component demonstrates enhanced skin lightening efficacy.
- the synergistic skin lightening component can be free from hydroquinone.
- the topical cosmetic composition in accordance with the presently described subject matter can comprise or consist of a skin lightening active component that exhibits synergistic skin lightening efficacy.
- the topical cosmetic composition in accordance with the presently described subject matter can comprise or consist of a skin lightening active component that exhibits synergistic skin lightening efficacy, wherein the topical cosmetic composition is free from hydroquinone.
- the topical cosmetic composition or the synergistic skin lightening system in accordance with the presently described subject matter, can comprise or consist of a skin lightening active component that exhibits synergistic skin lightening efficacy, wherein the topical cosmetic composition is free from hydroquinone and/or a flavan and/or a polyorganosiloxane-containing epsilon-polylysine compound.
- any non-toxic, inert, and effective topical cosmetically acceptable carrier may be used to formulate the compositions described herein.
- Well-known carriers used to formulate other topical therapeutic compositions for administration to humans are useful in these compositions. Examples of these components that are well known to those of skill in the art are described in The Merck Index, Thirteenth Edition, Budavari et al., Eds., Merck & Co., Inc., Rahway, N.J. (2001); the CTFA (Cosmetic, Toiletry, and Fragrance Association) International Cosmetic Ingredient Dictionary and Handbook, Tenth Edition (2004); and the "Inactive Ingredient Guide", U.S.
- the present subject matter relates to a topical cosmetic composition that can comprise at least one sunscreen.
- the at least one sunscreen can be present in an amount of from about 0.5% to about 30% by weight based on the total weight of the topical cosmetic composition, from about 1% by weight to about 20% by weight, or from about 1% by weight to about 10% by weight based on the total weight of the composition.
- Suitable sunscreens can include broad-spectrum sunscreens that protect against both UVA and UVB radiation, or sunscreen agents that protect against UVA or UVB radiation.
- the present topical cosmetic compositions can comprise a sunscreen comprising or consisting of one or more of methylene bis-benzotriazolyl tetramethylphenol, diethylamino hydroxybenzoyl hexyl benzoate, coated zinc oxide, ethylhexyl methoxycinnamate, isoamyl methoxycinnamate, homosalate ethyl hexyl salicilate, octocrylene, polysilicone-15, butyl methoxydibenzoylmethane, menthyl anthranilate, and ethylhexyl dimethyl PABA.
- a sunscreen comprising or consisting of one or more of methylene bis-benzotriazolyl tetramethylphenol, diethylamino hydroxybenzoyl hexyl benzoate, coated zinc oxide, ethylhexyl methoxycinnamate, isoamyl methoxycinnam
- the present topical cosmetic compositions can comprise a sunscreen comprising one or more of methylene bis-benzotriazolyl tetramethylphenol (TINOSORB M available from CIBA), diethylamino hydroxybenzoyl hexyl benzoate, and coated zinc oxide, in an amount of from about 1% to about 20% by weight, from about 2% to about 10% by weight, or of about 5% by weight, based on the total weight of the composition.
- a sunscreen comprising one or more of methylene bis-benzotriazolyl tetramethylphenol (TINOSORB M available from CIBA), diethylamino hydroxybenzoyl hexyl benzoate, and coated zinc oxide, in an amount of from about 1% to about 20% by weight, from about 2% to about 10% by weight, or of about 5% by weight, based on the total weight of the composition.
- the present topical cosmetic compositions can comprise a sunscreen comprising methylene bis-benzotriazolyl tetramethylphenol in an amount of from about 1% to about 20% by weight, from about 2% to about 10% by weight, or of about 5% by weight, based on the total weight of the composition
- the present topical cosmetic compositions can comprise a sunscreen comprising or consisting of one or more of ethylhexyl methoxycinnamate (available from BASF), isoamyl methoxycinnamate, homosalate ethyl hexyl salicilate, octocrylene, polysilicone-15, butyl methoxydibenzoylmethane, menthyl. anthranilate, and ethylhexyl dimethyl PABA, in an amount of from about 1% to about 10%, from about 5% to about 9%, or of about 7.5% by weight, based on the total weight of the composition.
- a sunscreen comprising or consisting of one or more of ethylhexyl methoxycinnamate (available from BASF), isoamyl methoxycinnamate, homosalate ethyl hexyl salicilate, octocrylene, polysilicone-15, buty
- the present topical cosmetic compositions can comprise one or more sunscreens in an amount of from about 0.5% by weight to about 30% by weight, from about 1% by weight to about 20% by weight, or from about 1% by weight to about 10% by weight based on the total weight of the composition.
- the at least one sunscreen can comprise or consist of a first sunscreen selected from the group consisting of methylene bis-benzotriazolyl tetramethylphenol, diethylamino hydroxybenzoyl hexyl benzoate, and coated zinc oxide; and a second sunscreen selected from the group consisting of ethylhexyl methoxycinnamate, isoamyl methoxycinnamate, homosalate ethyl hexyl salicilate, octocrylene, polysilicone-15, butyl methoxydibenzoylmethane, menthyl anthranilate, and ethylhexyl dimethyl PABA.
- a first sunscreen selected from the group consisting of methylene bis-benzotriazolyl tetramethylphenol, diethylamino hydroxybenzoyl hexyl benzoate, and coated zinc oxide
- a second sunscreen selected from the group consisting of ethyl
- the first sunscreen can be present in an amount of from about 1% to about 20% by weight, and the second sunscreen can be present in an amount of from about 1% to about 10% by weight, based on the total weight of the topical cosmetic composition.
- the first sunscreen can comprise or consist of methylene bis-benzotriazolyl tetramethylphenol, and the second sunscreen can comprise or consist of ethylhexyl methoxycinnamate.
- the present subject matter relates to a topical cosmetic composition that has an SPF of greater than about 10, has an SPF of greater than about 15, an SPF of at least about 15, an SPF of about 15, an SPF of from about 10 to about 45, an SPF of from about 15 to about 45, or an SPF of from about 15 to about 25.
- the present topical cosmetic compositions can additionally comprise an aqueous solvent.
- the present compositions comprise an aqueous solvent, for example, water, in an amount of from about 5% to about 95% by weight, from about 10% to about 90% by weight, from about 25% to about 80% by weight, from about 55% to about 75% by weight, from about 60% to about 70% by weight, or about 63% by weight, based on the total weight of the composition.
- Cosmetically Acceptable Excipients for example, water, in an amount of from about 5% to about 95% by weight, from about 10% to about 90% by weight, from about 25% to about 80% by weight, from about 55% to about 75% by weight, from about 60% to about 70% by weight, or about 63% by weight, based on the total weight of the composition.
- the present subject matter relates to a topical cosmetic composition that can comprise water and at least one cosmetically acceptable excipient.
- Suitable cosmetically acceptable excipients include those commonly known to one of ordinary skill in the art as useful in topical compositions.
- the at least one cosmetically acceptable excipient can comprise or consist of one or more members selected from the group consisting of an antioxidant, a chelating agent, a pH adjuster, an emollient, a thickening agent, gelling agent, free radical scavenger, a preservative, an emulsifier, a humectant, a moisturizer, a suspending agent, a surfactant, a stabilizer, a vitamin, a penetration enhancer, a perfume or fragrance, a coloring agent, fluid alkyl alcohols, polysiloxanes, modified polysiloxanes, and combinations thereof.
- the present topical cosmetic compositions are formulated in a serum, a gel cream, a lotion, a cream, an ointment, a gel, an aerosol, a foam, a foamable liquid, a solution (solubilized system), a paste, a suspension, a dispersion, an emulsion, a skin cleanser, a milk, a mask, a solid stick, a bar (such as a soap bar), an encapsulated formulation, a microencapsulated formulation, microspheres or nanospheres or vesicular dispersions, or other cosmetically acceptable topical dosage form.
- the lipids of which the vesicles are made can be of the ionic or nonionic type, or a mixture thereof.
- the formulation can comprise one or more of an aqueous formulation and/or an anhydrous formulation.
- the present topical cosmetic composition in accordance with the subject matter described herein can comprise or consist of an anhydrous formulation, an aqueous formulation, or an emulsion.
- the present topical cosmetic compositions in accordance with the subject matter described herein are formulated in a serum or a gel cream.
- the presently described topical cosmetic compositions can optionally further comprise one or more cosmetic active agents or dermatological active agents in addition to the described skin-lightening active agents.
- Such agents can include, for example, additional skin lightening active agents including plant derived and non-plant derived skin lightening agents, including for example, pigmentation inhibitors, tyrosinase inhibitors, and/or melanocyte melanogenesis inhibitors; and/or non-skin lightening active agents, including for example, optical brightening agents, sunscreen agents, anti-inflammatory agents, anti-microbial agents, anti-fungal agents, anti-wrinkle agents, anti-atrophy agents, anti-acne agents, free-radical scavengers, keratolytic agents, vitamins, anti-elastase and/or anti-collagenase agents, peptides, fatty acid derivatives, steroids, trace elements, extracts of algae and/or of planktons, enzymes and/or coenzymes, flavonoids and/or cer
- the present subject matter relates to a method of lightening skin pigmentation in a subject, comprising topically administering to skin of a subject in need thereof, a therapeutically effective amount of the topical cosmetic composition in accordance with the subject matter described herein.
- the present subject matter relates to a method of treating a skin disorder or condition in a subject, comprising topically administering to skin of a subject in need thereof, a therapeutically effective amount of the topical cosmetic composition in accordance with the subject matter described herein.
- the skin disorder or condition can be a disorder or condition associated with undesirable skin pigmentation.
- the present subject matter relates to a method of lightening skin pigmentation in a subject or treating a skin disorder or condition in a subject, comprising topically administering for at least once per day for at least three days, for at least five days, for at least seven days, for at least ten days, or for at least fourteen days, to skin of a subject in need thereof, a therapeutically effective amount of the topical cosmetic composition in accordance with the subject matter described herein.
- a therapeutically effective amount of the topical cosmetic composition in accordance with the subject matter described herein.
- the skin is visibly altered.
- the present subject matter relates to a method of lightening skin pigmentation in a subject or treating a skin disorder or condition in a subject, comprising topically administering for at least once per day for at least three weeks to skin of a subject in need thereof, a therapeutically effective amount of the topical cosmetic composition in accordance with the subject matter described herein, wherein after three weeks the skin is visibly lightened.
- the present topical cosmetic compositions are effective in treating a variety of skin disorders or conditions characterized by undesirable skin pigmentation.
- disorders and/or conditions can include regional hyperpigmentation caused by melanocy e hyperactivity such as idiopathic melasma occurring during pregnancy (mask of pregnancy or chloasma) or secondary to estrogen-progesterone contraception; local hyperpigmentation caused by benign melanocyte hyperactivity and proliferation such as lentigo senilis, known as liver spots; accidental hyperpigmentation such as post-lesional photosensitization and scarring; freckles; malpigmentation; and certain forms of leukoderma such as vitiligo where, if the injured skin cannot be repigmented, the residual zones of normal skin are lightened or depigmented to impart a homogeneous color to the entire skin.
- Skin can be treated according to the presently described methods for purely cosmetic lightening of areas, for example, large areas, of skin whose pigmentation, although undesired, is adequate for the individual skin type.
- the skin disorder or condition to be treated according to the present methods is undesired skin pigmentation.
- the present subject matter relates to a method of treating a skin disorder or condition in a subject, or to a method of lightening skin pigmentation in a subject, wherein topically administering to skin comprises administering at least once per day or at least twice per day for a period of at least two weeks, at least 3 weeks, or at least 4 weeks, wherein skin pigmentation is lightened.
- compositions of the present topical cosmetic compositions in accordance with the presently described subject matter can be readily produced by the skilled artisan according to known methods of producing such formulations including for example, a cream, a gel, a serum, a lotion, or other formulation described herein, without undue experimentation.
- a process for producing a cream or emulsion formulation can comprise separately producing an aqueous phase and an oil phase, adding the oil phase to the aqueous phase, for example with mixing and/or homogenization (with high shear), to an emulsion.
- one or more of the following components can be optionally added thereto, for example, in the following order, to produce the final emulsion or cream: one or more skin lightening actives; one or more pH adjusters; one or more emollients; one or more skin lightening actives; one or more sunscreen actives; one or more thickening agents; one or more antioxidants; and one or more fragrances.
- the aqueous phase and the oil phase Prior to forming the emulsion, can be separately heated to a temperature of from about 70°C to about 99°C; from about 75°C to about 95°C; from about 80 0 C to about 90°C; or about 85°C. After heating the oil phase can be slowly added to the aqueous phase, for example, with mixing and high shear homogenization. The resultant emulsion can then be cooled while maintaining mixing and high shear homogenization, for example, to a temperature of from about 47 0 C to about 27°C; from about 42 0 C to about 30°C; from about 39°C to about 35°C; or about 37°C.
- the produced emulsion or cream can have a pH of from about 4.5 to 6.5 and/or a viscosity of from about 5,000 cP to about 15,000 cP and/or a density of from about 1.01 to about 1.06.
- compositions produced according to the above-described processes. If produced according to these processes, these compositions exhibit chemical and physical stability suitable for topical administration.
- the topical cosmetic compositions produced according to these processes can be placed in a suitable containment vessel comprising a product contact surface composed of a material selected from the group consisting of glass, plastic, steel, stainless steel, aluminum, Teflon, polymeric structure, ceramic structure, alloys, and mixtures thereof.
- a suitable containment vessel comprising a product contact surface composed of a material selected from the group consisting of glass, plastic, steel, stainless steel, aluminum, Teflon, polymeric structure, ceramic structure, alloys, and mixtures thereof.
- These containment vessels are used to facilitate manufacturing, handling, processing, packaging, storage, and administration of said topical cosmetic composition.
- Suitable containment vessels in this regard can be selected from the group consisting of plastic tubes, bottles, metal tubes, and any combination thereof.
- Appropriate dosage levels for the active agents contemplated in the present topical cosmetic compositions and methods are well known to those of ordinary skill in the art and are selected to maximize the treatment of the above skin conditions. Dosage levels on the order of about 0.001 mg to about 5,000 mg per kilogram body weight of the skin lightening active components are known to be useful in the treatment of the diseases, disorders, and conditions contemplated herein. Typically, this effective amount of the skin lightening active components will generally comprise from about 0.001 mg to about 100 mg per kilogram of patient body weight per day. Moreover, it will be understood that this dosage of ingredients can be administered in a single or multiple dosage units to provide the desired therapeutic effect.
- compositions can be combined with other therapeutic agents in conjunction with those provided in the above-described compositions.
- amount of active ingredients that may be combined with the carrier materials to produce a single dosage form will vary depending upon the host treated, the nature of the disease, disorder, or condition, and the nature of the active ingredients.
- the present compositions may be given in a single dose or multiple doses daily.
- the present topical cosmetic compositions are given from one to four times daily. Starting with a low dose once or twice daily and slowly working up to higher doses if needed is a strategy.
- the amount of active ingredients that may be combined with the carrier materials to produce a single dosage form will vary depending upon the host treated, the nature of the disease, disorder, or condition, and the nature of the active ingredients.
- the topical cosmetic compositions may be topically applied once or multiple times per day.
- the present topical cosmetic compositions are topically applied from one to four times daily. For example, starting with once daily and progressing to more frequent applications, if needed, is one strategy.
- the present topical cosmetic compositions are topically applied from one to four times daily, for example, in the morning, at noon, in the afternoon, and/or in the evening.
- the topical cosmetic compositions as described herein can be administered once or multiple times per day for a period of time of at least one week, for a period of at least two weeks, for a period of at least four weeks, or for a period of at least eight weeks.
- the topical cosmetic compositions can be administered once or multiple times per day for a period of time of up to one year, of up to six months, of up to three months, or of up to two months .
- a specific dose level for any particular patient will vary depending upon a variety of factors, including the activity of the specific active agent; the age, body weight, general health, sex and diet of the patient; the time of administration; the rate of excretion; possible drug combinations; the severity of the particular condition being treated; and the form of administration.
- One of ordinary skill in the art would appreciate the variability of such factors and would be able to establish specific dose levels using no more than routine experimentation.
- Pharmacokinetic parameters such as bioavailability, absorption rate constant, apparent volume of distribution, unbound fraction, total clearance, fraction excreted unchanged, first-pass metabolism, elimination rate constant, half-life, and mean residence time are well known in the art.
- the optimal cosmetic formulations can be determined by one skilled in the art depending upon considerations such as the particular ingredients and the desired dosage. See, for example, Remington 's Pharmaceutical Sciences, 18th ed. (1990, Mack Publishing Co., Easton, PA 18042), pp. 1435-1712, and "Harry's Cosmeticology", 8th ed. (2000, Chemical Publishing Co., Inc., New York, N. Y. 10016), the disclosure of each of which is hereby incorporated by reference herein in its entirety. Such formulations may influence the physical state, stability, rate of in vivo release, and rate of in vivo clearance.
- the present topical cosmetic composition in accordance with the subject matter described herein may be a gel cream packaged in, for example, a tube, or a serum packaged in, for example, a non-aerosol non-foaming pump container or bottle, wherein the amount of the composition contained in the container can be in the range of from about 10 gm to about 60 gm, between about 20 gm and about 50 gm, or about 30 gm, or about 40 gm.
- Single dosage kits and packages containing once per day amount of composition may be prepared.
- Single dose, unit dose, and once-daily disposable containers of the present compositions are contemplated as within the scope of the present subject matter.
- compositions in accordance with the subject matter described herein may be formulated for storage in a substantially non-reactive laminated package to enhance stability of the package. This method of storage provides enhanced package stability in comparison with other, paper-based packages.
- the amount of composition per single packet may range be from about 0.1 ml to about 20.0 ml, between about 0.5 and about 5.0 ml, or between about 1 and about 3 ml.
- compositions capable of long term storage are also contemplated.
- present compositions remain unexpectedly stable in storage for periods including between about 3 months and about 3 years, about 3 months and about 2.5 years, between about 3 months and about 2 years, between about 3 months and about 20 months, and alternately any time period between about 6 months and about 18 months.
- the presently described topical cosmetic formulation in accordance with the subject matter described herein remains stable for at least three years at a temperature of less than 30°C. In an embodiment, the presently described topical cosmetic formulation remains stable for at least two years at a temperature of less than or equal to 30°C. In an embodiment, the presently described topical cosmetic formulation remains stable for at least two years at a temperature of less than or equal to 25°C.
- any polymer molecular weights are mean average molecular weights. All percentages are based on the percent by weight of the final delivery system or formulation prepared unless otherwise indicated and all totals equal 100% by weight.
- the color is expressed by a system of three-dimensional coordinates where the L* axis corresponds to skin luminosity, the a* axis corresponds to green and red colors, and the b* axis corresponds to blue and yellow colors.
- CO was used as the light source.
- This equipment provides continuous light emission in the UVB and UVA spectrum, ranging between 290 and 400nm.
- the device includes a set of lenses and filters that absorb or disperse irradiation lower than 320nm or higher than 400nm.
- the irradiation occurs through a set of 6 branches of optic fiber called "ports", programmed to apply pre-established individual doses of irradiation. Irradiation monitoring was performed using a Dose Controlling System (DCS), which includes a UVB irradiation detector and an electronic monitor. In this study, only three "ports" were used for each application site of the tested compositions.
- DCS Dose Controlling System
- the present topical cosmetic composition comprising:
- Phenoxyethanol and methylisothiazolinone preservative 0.6
- This formulation has a pH ranging from 4.5-6.5; a viscosity ranging from 5,000 to 15,000 cP; and a density ranging from 1.01 to 1.06.
- This alternative method achieved a change in formulation pH from a pH ranging from 4.0 to 6.5 to a pH ranging from 5.0 to 6.5.
- Extract of licorice, extract of bellis perennis and emblica were generally kept under yellow light and/or protected from exposure to white light.
- the entire process, including packaging preferably takes place under yellow light.
- the resulting formulation is stored without exposure to white light and air. Premixes
- Premix A In an additional suitable container add Tinosorb M® (Methylene Bis- Benzotriazolyl Tetramethylbutylphenol (and) Decyl Glucoside (and) Xanthan Gum (and) Propylene glycol (and) Water and Purified Water 2 nd Portion. Agitate until totally dispersed. Reserve.
- Tinosorb M® Methylene Bis- Benzotriazolyl Tetramethylbutylphenol (and) Decyl Glucoside (and) Xanthan Gum (and) Propylene glycol (and) Water and Purified Water 2 nd Portion. Agitate until totally dispersed. Reserve.
- Premix B In an additional suitable container add DC9040® (Dimethicone Crosspolymer (and) Cyclomethicone and DC5225C® (Cyclopentasiloxane/PEG/PPG-18/18 Dimethicone). Agitate until totally dispersed. Reserve.
- Premix C In an additional suitable container add Propylene Glycol and Licorice Extract. Agitate until totally dissolved. Reserve.
- Premix D In an additional suitable container add Emblica and Purified Water 3 rd Portion Agitate until totally dispersed. Reserve.
- Neolone PE ® Phhenoxyethanol (and) Methylisothiazolinone
- Premix B Premix B
- Premix C Premix C
- Belides® Extract of Bellis Perennis
- Age level 18 to 60 years old
- Photo-induced pathologies such as sun hives, lupus erythematosus, polyform rash at light, recurring herpes simplex;
- MED minimum erythematose dose
- the individual Minimum Erythematose Dose is defined as the minimum ultraviolet (UV) radiation dose necessary to produce clear and well-defined contour erythema at the exposure site, which was used as a reference during the test stage.
- each test site located on the back, between the pelvic and scapular waist, laterally to the medial line of the spine, was marked with the volunteer in a horizontal position and using a marker.
- Three sites indicated for the application of the products were delimited, i.e., Site B, Site E, and Site F. Each site was 35 cm 2 (07 x 05cm).
- irradiation equivalent to 1.5 times the minimum erythematose dose, previously calculated for each volunteer was applied. This application was repeated twice whereby each site was irradiated a total of three times.
- Site E The present topical cosmetic composition
- FIG. 1 illustrates progressive lightening over time that becomes statistically significant after 21 days.
- Table III shows the results of the comparison test between the L * of TO averages and the other experimental times for area 1 (Site B).
- Talbe IV shows the raw data for the individual results for the area 1 (Site B) for each volunteer in term of L * , a*, and b* for each of TO, T07, T14, and T21.
- Figure 2 illustrates the results obtained for Site E, i.e., the application location of the evaluated present topical cosmetic composition. Figure 2 illustrates that there is progressive lightening over time that becomes statistically significant after 14 days.
- Table V below illustrates the results of the comparison test between the L * of TO averages and the other experimental times for area 2 (Site E).
- Table VI shows the raw data for the individual results for area 2 (Site E) for each volunteer in term of L * , a*, and b* for each of TO, T07, T14, and T21.
- Figure 3 illustrates, for the control location Site F, i.e., where there was no treatment for the irradiation, progressive lightening (natural degradation of the synthesized melanin), without any significance over the experimental times.
- Table VII shows the results of the comparilson test between the L * of TO averages and the other experimental times for the control area (Site F).
- Table VIII shows the raw data for the individual results for the control area (Site F) for each volunteer in term of L * , a*, and b* for each of TO, T07, T14, and T21.
- Figure 4 illustrates the comparison between the averages of the colorimetric values in treatments 1 and 2 and the control over the evaluation times.
- Table IX illustrates that only the present topical cosmetic formulation exhibited statistically significant reduction in pigmentation as compared to the spontaneous reduction in pigmentation observed in the control group. TABLE IX
- the colorimeter was used as a complementary instrumental evaluation, enabling the detection of differences which the human eye cannot detect.
- the L* parameter provided by the colorimetric measurement is the index directly related to the skin's luminosity. The higher the value of L* the lighter the evaluated region.
- Hydroquinone significantly improves as from T21;
- the present topical cosmetic composition significantly improves as from T 14, with statistically significant higher lightening levels when compared to the control. Accordingly, the present topical cosmetic composition provided a faster and more significant lightening effect (provides a higher lightening index) as compared to hydroquinone.
- Figure 5 shows photographs of clinical data supporting the colorimetric results, where the greater average lightening effect was obtained on the location with the new formula.
- the hydroquinone treatment and the new formulation were similar at the end of the study, although the new formulation is faster and provides a higher lightening index.
- Phenoxyethanol and methylisothiazolinone preservative .6
- the composition is prepared as in Example 1. More specifically, after Premix E is added to the emulsion, Neolone PE (Phenoxiethanol and Methylisothiazolinone) and cyclomethicone are added under high shearing homogenization and mixing for about 15 minutes. The thickening agents including xanthan gum are added in the oil phase.
- Neolone PE Phenoxiethanol and Methylisothiazolinone
- cyclomethicone are added under high shearing homogenization and mixing for about 15 minutes.
- the thickening agents including xanthan gum are added in the oil phase.
- a topical cosmetic composition is administered topically to the skin of a subject being treated by conventional means. This is preferably done through the use of a serum or cream gel formulation. A topical preparation may thus be applied to the desired skin surface area with, for example, the use of the fingertips.
- the subject For topical administration of the cosmetic composition, the subject should be told to first clean the affected area gently and to pat it dry. The topical cosmetic composition may then be applied directly to the affected skin area or dispensed into the palm of the hand or suitable vessel from which material may be taken and manually applied to the skin area to be treated.
- a subject is suffering from undesired skin pigmentation.
- a topical cosmetic composition as described herein is topically administered to undesirably pigmented areas of the skin of the subject. It would be expected that the undesirably pigmented areas of the skin of the subject would be lightened.
- a subject is suffering from vitiligo.
- a topical cosmetic composition as described herein is topically administered to the residual areas of normal skin of the subject. It would be expected that the residual areas of normal skin of the subject would be lightened to impart a homogeneous color to the entire skin.
- a subject is suffering from age spots.
- a topical cosmetic composition as described herein is topically administered to the affected skin areas of the subject. It would be expected that the age spots would be lightened.
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Epidemiology (AREA)
- Birds (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Dermatology (AREA)
- Cosmetics (AREA)
Abstract
Description
Claims
Priority Applications (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2008364312A AU2008364312B2 (en) | 2007-11-19 | 2008-11-19 | Topical cosmetic skin lightening compositions |
PCT/US2008/012952 WO2010059140A1 (en) | 2008-11-19 | 2008-11-19 | Topical cosmetic skin lightening compositions |
US12/743,353 US9241893B2 (en) | 2007-11-19 | 2008-11-19 | Topical cosmetic skin lightening compositions and methods of use thereof |
MX2010005549A MX2010005549A (en) | 2008-11-19 | 2008-11-19 | Topical cosmetic skin lightening compositions. |
CA 2706992 CA2706992C (en) | 2007-11-19 | 2008-11-19 | Topical cosmetic skin lightening compositions and methods of use thereof |
JP2011536292A JP2012509257A (en) | 2008-11-19 | 2008-11-19 | Topical whitening cosmetic composition and method of use |
BRPI0819683A BRPI0819683B1 (en) | 2008-11-19 | 2008-11-19 | topical cosmetic composition and non therapeutic cosmetic method for whitening skin pigmentation |
US14/950,395 US9364424B2 (en) | 2007-11-19 | 2015-11-24 | Topical cosmetic skin lightening compositions and methods of use thereof |
US14/950,451 US20160074316A1 (en) | 2007-11-19 | 2015-11-24 | Topical cosmetic skin lightening compositions and methods of use thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/US2008/012952 WO2010059140A1 (en) | 2008-11-19 | 2008-11-19 | Topical cosmetic skin lightening compositions |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2007/024109 Continuation-In-Part WO2009067095A1 (en) | 2007-11-19 | 2007-11-19 | Topical cosmetic skin lightening compositions and methods of use thereof |
Related Child Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/743,353 A-371-Of-International US9241893B2 (en) | 2007-11-19 | 2008-11-19 | Topical cosmetic skin lightening compositions and methods of use thereof |
US14/950,451 Continuation US20160074316A1 (en) | 2007-11-19 | 2015-11-24 | Topical cosmetic skin lightening compositions and methods of use thereof |
US14/950,395 Continuation-In-Part US9364424B2 (en) | 2007-11-19 | 2015-11-24 | Topical cosmetic skin lightening compositions and methods of use thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2010059140A1 true WO2010059140A1 (en) | 2010-05-27 |
Family
ID=42198380
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2008/012952 WO2010059140A1 (en) | 2007-11-19 | 2008-11-19 | Topical cosmetic skin lightening compositions |
Country Status (4)
Country | Link |
---|---|
JP (1) | JP2012509257A (en) |
BR (1) | BRPI0819683B1 (en) |
MX (1) | MX2010005549A (en) |
WO (1) | WO2010059140A1 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2771032A1 (en) * | 2011-10-29 | 2014-09-03 | Merck Patent GmbH | Skin lightener in phototherapy |
US9655833B2 (en) | 2009-07-29 | 2017-05-23 | Elise OLSEN | Compositions and methods for inhibiting hair growth |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2017425084B2 (en) * | 2017-07-26 | 2023-07-27 | Chemisches Laboratorium Dr. Kurt Richter Gmbh | Topical herbal compositions |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20010016213A1 (en) * | 1996-12-28 | 2001-08-23 | Singh-Verma Shyam B. | Cosmetic formulations containing extracts from phyllanthus emblica and centella asiatica and/or bacopa monnieri |
US20040175439A1 (en) * | 2001-03-02 | 2004-09-09 | Benoit Cyr | Plant extracts and compositions comprising extracellular protease inhibitors |
US20060018867A1 (en) * | 2004-05-12 | 2006-01-26 | Ichimaru Pharcos Co., Ltd | Cosmetic composition and production thereof |
WO2006053912A1 (en) * | 2004-11-22 | 2006-05-26 | Symrise Gmbh & Co. Kg | Formulations comprising ceramides and/or pseudoceramides and (alpha-)bisabolol for combating skin damage |
US20060280704A1 (en) * | 2003-12-23 | 2006-12-14 | Sabrina John | Topical depigmenting formulations comprising an extract of bellis perennis |
US20070122492A1 (en) * | 2004-11-18 | 2007-05-31 | Stephen Behr | Plant extracts and dermatological uses thereof |
-
2008
- 2008-11-19 WO PCT/US2008/012952 patent/WO2010059140A1/en active Application Filing
- 2008-11-19 JP JP2011536292A patent/JP2012509257A/en not_active Withdrawn
- 2008-11-19 BR BRPI0819683A patent/BRPI0819683B1/en not_active IP Right Cessation
- 2008-11-19 MX MX2010005549A patent/MX2010005549A/en not_active Application Discontinuation
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20010016213A1 (en) * | 1996-12-28 | 2001-08-23 | Singh-Verma Shyam B. | Cosmetic formulations containing extracts from phyllanthus emblica and centella asiatica and/or bacopa monnieri |
US20040175439A1 (en) * | 2001-03-02 | 2004-09-09 | Benoit Cyr | Plant extracts and compositions comprising extracellular protease inhibitors |
US20060280704A1 (en) * | 2003-12-23 | 2006-12-14 | Sabrina John | Topical depigmenting formulations comprising an extract of bellis perennis |
US20060018867A1 (en) * | 2004-05-12 | 2006-01-26 | Ichimaru Pharcos Co., Ltd | Cosmetic composition and production thereof |
US20070122492A1 (en) * | 2004-11-18 | 2007-05-31 | Stephen Behr | Plant extracts and dermatological uses thereof |
WO2006053912A1 (en) * | 2004-11-22 | 2006-05-26 | Symrise Gmbh & Co. Kg | Formulations comprising ceramides and/or pseudoceramides and (alpha-)bisabolol for combating skin damage |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9655833B2 (en) | 2009-07-29 | 2017-05-23 | Elise OLSEN | Compositions and methods for inhibiting hair growth |
US9707169B2 (en) | 2009-07-29 | 2017-07-18 | Elise OLSEN | Compositions and methods for inhibiting hair growth |
US10159634B2 (en) | 2009-07-29 | 2018-12-25 | Elise A. Olsen | Compositions and methods for inhibiting hair growth |
EP3871671A2 (en) | 2009-07-29 | 2021-09-01 | Olsen, Elise | Fp receptor antagonists for inhibiting hair growth |
EP2771032A1 (en) * | 2011-10-29 | 2014-09-03 | Merck Patent GmbH | Skin lightener in phototherapy |
Also Published As
Publication number | Publication date |
---|---|
MX2010005549A (en) | 2010-08-16 |
BRPI0819683A2 (en) | 2016-10-18 |
BRPI0819683A8 (en) | 2016-11-22 |
BRPI0819683B1 (en) | 2017-04-04 |
JP2012509257A (en) | 2012-04-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US9241893B2 (en) | Topical cosmetic skin lightening compositions and methods of use thereof | |
US20210251869A1 (en) | Skin treatment methods | |
US11964039B2 (en) | Compositions that brighten skin, provide sun protection, and permit vitamin D production | |
US20090028969A1 (en) | Compostion for treating skin | |
JP2011504498A (en) | Topical whitening cosmetic composition and method of use | |
US9364424B2 (en) | Topical cosmetic skin lightening compositions and methods of use thereof | |
US10532024B2 (en) | Topical compositions of Lithospermum erythrorhizon (gromwell root) for treating or controlling excessive oil production in skin and minimizing glycation in skin, and methods of using the compositions | |
WO2008121315A2 (en) | Compositions and methods for inhibiting melanogenesis | |
US20200306172A1 (en) | Depigmenting dermatological and cosmetic compositions | |
EP2482830B1 (en) | Extracts of phyllanthus niruri | |
TWI523666B (en) | Compositions comprising lilium martagon extracts and uses thereof | |
AU2008364312B2 (en) | Topical cosmetic skin lightening compositions | |
ES2584502T3 (en) | New use of cocoa polyphenols for cell cycle regulation in the treatment of hyperkeratinization | |
FR2723316A1 (en) | Compsn. for skin de-pigmentation caused by hyper:activation melanocytes | |
WO2010059140A1 (en) | Topical cosmetic skin lightening compositions | |
KR20050117958A (en) | Topical nano liposome formulation including extracted purified herbal mixture and whitening cosmetics using this formulation | |
KR102275267B1 (en) | Composition for improving skin | |
JP4041243B2 (en) | Whitening cosmetics | |
JP2731329B2 (en) | Skin cosmetics | |
KR102338361B1 (en) | Composition for improving skin | |
US20100061948A1 (en) | Composition for skin whitening comprising artemisinine | |
JP3197651B2 (en) | Skin cosmetics | |
CN116350531A (en) | Anti-glycation application of opal D | |
KR20210117247A (en) | Composition for improving skin comprising stevioside as active ingredient | |
CN116473858A (en) | Whitening application of opal D |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 2011536292 Country of ref document: JP Ref document number: 2706992 Country of ref document: CA Ref document number: MX/A/2010/005549 Country of ref document: MX |
|
ENP | Entry into the national phase |
Ref document number: 2008364312 Country of ref document: AU Date of ref document: 20081119 Kind code of ref document: A |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 08878317 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 12743353 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
32PN | Ep: public notification in the ep bulletin as address of the adressee cannot be established |
Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205A DATED 31/08/2011) |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 08878317 Country of ref document: EP Kind code of ref document: A1 |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01E Ref document number: PI0819683 Country of ref document: BR Free format text: ESCLARECA A DIVERGENCIA NA DATA DO DEPOSITO INTERNACIONAL QUE CONSTA NA PUBLICACAO INTERNACIONAL WO 2010/059140 DE 27/05/2010 COMO "19/11/2008" E O CONSTANTE DA PETICAO INICIAL NO 020100047619 DE 27/05/2010 COMO "14/11/2008". |
|
ENP | Entry into the national phase |
Ref document number: PI0819683 Country of ref document: BR Kind code of ref document: A2 Effective date: 20100527 |